Clinical Trial IDNCT04140526
Lead SponsorOncoImmune, Inc.
Principal Investigator
Start Date2020-02-01
Completion Date2023-02-01
Study TypeInterventional
PhasePhase 1
StatusNot yet recruiting


This is a First-in-Human Phase IA/IB open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.


Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate CancerDrug: ONC-392, Drug: PembrolizumabPhase 1


AgeGenderAccepts Healthy Volunteers
18 Years and older.AllNo